The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05961202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 200 participants
- Registry
-
NCT05961202
-
- Other papers using this trial's data
- The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy: a multicenter randomized study (HYPIC trial)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05961202. Randomized; single masking; primary purpose treatment. Start 2021-11-01 (actual); primary completion 2024-09-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
- Acronym
- HYPIC
- Condition
- Inflammatory Cardiomyopathy
- Condition
- Myocarditis
- Intervention (Drug)
- Hydroxychloroquine
- Intervention (Drug)
- Prednisolone
- Lead sponsor
- Tongji Hospital
- Collaborator
- Wuhan Central Hospital
- Collaborator
- Taihe Hospital
Record details
- Record id
cardio:ct-nct05961202- Content hash
a2000ee727f28034b7dc3dad4b1cb3124fcca73189a328e5c041031aabef59ff